Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses
about
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsElucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulationsCurrent perspectives on HIV-1 antiretroviral drug resistanceCrystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug DesignHIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanismHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateInhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymeraseHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityInvestigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations.Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.Recent findings on the mechanisms involved in tenofovir resistance.Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole AnalogsHIV-1 reverse transcriptase and antiviral drug resistance. Part 2.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence.New in silico and conventional in vitro approaches to advance HIV drug discovery and design.A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us?Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.Antileishmanial activity of antiretroviral drugs combined with miltefosine.Docking Field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
P2860
Q24652511-E1942D29-FF7A-45B1-A7C6-7AC5D15BE8D4Q24654012-6FF7A4C4-33A9-42F9-AA33-89A3F1FF6A5BQ26852626-AE944E99-F555-4899-8A95-943A11BE525CQ27675166-86D97574-D544-4AF2-96B0-EF0C919AF9A6Q27676835-F9239FF2-45FD-4428-B89A-3D89A6AA7928Q28250395-27C687C1-1FA8-4A02-8BAD-FC577F200891Q28476610-DA39352B-D8BA-4AB7-83E7-815BF1F3D55CQ28478993-90882F74-AF1C-45FE-9C00-4EDE0C888C9CQ28533996-60732A55-566E-4B9E-9B9D-2C2BF0B15A3EQ30456752-9A64AB77-A9ED-4AEB-ABEA-D6C8093FCB2DQ33649797-B69456E7-F8DF-41B4-AB00-AD4BBD9E3DE6Q33826904-D4729499-1EBE-4F7D-A0C6-33EDA995EA92Q33831709-DE171493-3485-449B-A85A-9C6F8FF7AE8AQ33900264-0E0FA088-3054-48C5-B7EC-51DE91B67928Q33900459-65511A29-3559-471B-B9D9-460C1FCD5DF2Q34094395-DA11B2DA-90FE-4847-A238-0B3249AE9BEBQ34313002-C20CA0DF-7D90-477F-B75E-271D7D3F3106Q34483539-05E3364D-D55B-4196-B246-FD7DA0FCC195Q35105821-4A7DAEE5-3DED-4B49-96A5-4F7A26877A49Q36939750-ABD84A1E-B59E-41CB-B8BE-A7BFCE06470DQ37145329-41897ED2-DAAA-49A7-AA16-6321A058743CQ38612672-F3D0C919-8F0B-4558-ADD4-C34D3D3EDE28Q38620336-B4123229-BF4F-4021-82C9-50C49C818841Q38954255-F0D9480C-8625-4CB8-8783-0AD85C4BF697Q40080043-231BBAA6-F278-452B-AC7A-A4FED5C26E6BQ41040182-2FE01846-44DA-4671-B3FA-9ABB0D109B5AQ42738742-FFCE127E-AA03-4020-BAC7-84687A9FC61FQ44742776-1C648551-8660-4516-8A29-97B2E69C0C01Q54567693-848CB929-BA18-4536-A62B-5978FBA672E2
P2860
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Probing nonnucleoside inhibito ...... by transient kinetic analyses
@ast
Probing nonnucleoside inhibito ...... by transient kinetic analyses
@en
type
label
Probing nonnucleoside inhibito ...... by transient kinetic analyses
@ast
Probing nonnucleoside inhibito ...... by transient kinetic analyses
@en
prefLabel
Probing nonnucleoside inhibito ...... by transient kinetic analyses
@ast
Probing nonnucleoside inhibito ...... by transient kinetic analyses
@en
P2093
P2860
P356
P1433
P1476
Probing nonnucleoside inhibito ...... by transient kinetic analyses
@en
P2093
Jessica Radzio
Karen S Anderson
Nicolas Sluis-Cremer
P2860
P304
P356
10.1110/PS.072829007
P577
2007-08-01T00:00:00Z